nach oben

Erschienen in:

01.02.2016 | Original paper

Grand multiparity and reproductive cancer in the Jerusalem Perinatal Study Cohort

verfasst von: Ora Paltiel, Salman M. Tajuddin, Yelena Polanker, Shoshanah Yazdgerdi, Orly Manor, Yechiel Friedlander, Susan Harlap, Ronit Calderon-Margalit

Erschienen in: Cancer Causes & Control | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Grand multiparity is associated with reduced mortality from reproductive cancers. We aimed to separate the components of mortality, by measuring incidence of and survival after reproductive cancer onset in grand multiparous compared to other parous women.

Study design

We linked data from the population-based Jerusalem Perinatal Study Cohort, which included women aged 13–55 who delivered 1964–1976, with Israel’s National Cancer Registry. We compared breast and gynecologic cancer risk and all-cause survival following a cancer diagnosis, among grand multiparae (GMPs = parity 5+, n = 8,246) versus women with parity 1–4 (n = 19,703), adjusting for reproductive and demographic variables.

Results

Grand multiparae were at significantly lower risk of breast cancer than others (adjusted hazard ratio (HR_adj) = 0.62, 95 % confidence interval (CI) 0.54–0.71), after controlling for age at first birth, education, and other covariates. This reduction was greater among GMPs whose first birth occurred after age 30 (p-interaction = 0.0001) and for cancer occurring before age 50 years (p = 0.002). In contrast, GMPs were at greater risk of death than women with parity <5, following a breast cancer diagnosis (HR_adj = 1.69, CI 1.39–2.1). Ovarian, uterine, and cervical cancer incidence did not differ between the groups, but survival was reduced for GMPs with uterine cancer (HR_adj = 2.48, CI 1.22–5.03).

Conclusion

Reduced reproductive cancer mortality reported among GMPs masks two opposing phenomena: decreased breast cancer risk and poorer survival after breast and uterine cancers. The latter unfavorable outcome suggests that tumors in GMPs may be particularly aggressive, having perhaps escaped protective mechanisms conferred by parity. This finding calls for heightened clinical attention in this group.

Nur mit Berechtigung zugänglich

Bai J, Wong FWS, Bauman A, Mohsin M (2002) Parity and pregnancy outcomes. Am J Obstet Gynecol 186(2):274–278PubMedCrossRef

Omoloe-Ohonsi A, Ashimi AO (2011) Grand multiparity: obstetric performance in Aminu Kano teaching hospital, Kano, Nigeria. Niger J Clin Pract 14(1):6–9CrossRef

Rizk DEE, Khalfan M, Ezimokhai M (2001) Obstetric outcome in grand multipara in the United Arab Emirates: a case control study. Arch Gynecol Obstet 264(4):194–198PubMedCrossRef

Simmons D, Shaw J, McKenzie A, Eaton S, Cameron AJ, Zimmet P (2006) Is grand multiparity associated with an increased risk of dysglycaemia? Diabetologia 49(7):1522–1527PubMedCrossRef

Solomons B (1934) The dangerous multipara. Lancet 224(5784):8–11CrossRef

Schechter Y, Levy A, Wiznitzer A, Zlotnik A, Sheiner E (2010) Obstetric complications in grand and great grand multiparous women. J Matern-Fet Neonatal Med 23(10):1211–1217CrossRef

Aliyu MH, Jolly PE, Ehiri JE, Salihu HM (2005) High parity and adverse birth outcomes: exploring the maze. Birth 32(1):45–59PubMedCrossRef

Rortveit G, Hannestad YS, Dalveit AK, Hunskaar S (2001) Age- and type-dependent effects of parity on urinary incontinence: the Norwegian EPINCONT study. Obstet Gynecol 98(6):1004–1010PubMedCrossRef

Jacobsen BK, Knutsen SF, Oda K, Fraser GE (2011) Parity and total, ischemic heart disease and stroke mortality. The Adventist health study, 1976–1988. Eur J Epidemiol 26(9):711–718PubMedPubMedCentralCrossRef

10.

Hinkula M, Kauppila A, Nayha S, Pukkala E (2006) Cause-specific mortality of grand multiparous women in Finland. Am J Epidemiol 163(4):367–373PubMedCrossRef

11.

Koski-Rahikkala H, Pouta A, Pietilainen K, Hartikainen A-L (2006) Does parity affect mortality among parous women? J Epidemiol Community Health 60(11):968–973PubMedPubMedCentralCrossRef

12.

Dior U, Hochner H, Friedlander Y et al (2013) Association between number of children and mortality of mothers: results of a 37-year follow-up study. Ann Epidemiol 23(1):13–18PubMedPubMedCentralCrossRef

13.

Chan TF, Wu CH, Changchien CC, Yang CY (2011) Mortality from breast, endometrial and ovarian cancers among grand multiparous women in Taiwan. Aust NZ J Obstet Gynaecol 51(6):548–552CrossRef

14.

Strand BH, Tverdal A, Claussen B, Zahl P-H (2005) Is birth history the key to highly educated women’s higher breast cancer mortality? A follow-up study of 500,000 women aged 35–54. Int J Cancer 117(6):1002–1006PubMedCrossRef

15.

Jaffe DH, Eisenbach Z, Manor O (2011) The effect of parity on cause-specific mortality among married men and women. Matern Child Health J 15(3):376–385PubMedCrossRef

16.

Martinez G, Daniels K, Chandra A (2012) Fertility of men and women aged 15–44 years in the United States: National Survey of Family Growth, 2006–2010. National Health Statistics Reports 51. www.cdc.gov/nchs/data/nhsr.nhsr051.pdf. Accessed 28 Oct 2015

17.

Lenora J, Lekamwasam S, Karlsson MK (2009) Effects of multiparity and prolonged breast-feeding on maternal bone mineral density: a community-based cross-sectional study. BMC Women’s Health 9:19PubMedPubMedCentralCrossRef

18.

Kauppila A, Kyyronen P, Hinkula M, Pukkala E (2009) Birth intervals and breast cancer risk. Br J Cancer 101(7):1213–1217PubMedPubMedCentralCrossRef

19.

Liu Q, Wuu J, Lambe M, Hsieh SF, Ekbom A, Hsieh CC (2002) Transient increase in breast cancer risk after giving birth: postpartum period with the highest risk (Sweden). Cancer Causes Control 13(4):299–305PubMedCrossRef

20.

Albrektsen G, Heuch I, Kvale G (1995) The short-term and long-term effect of a pregnancy on breast cancer risk: a prospective study of 802,457 parous Norwegian women. Br J Cancer 72(2):480–484PubMedPubMedCentralCrossRef

21.

MacMahon B, Cole P, Lin TM et al (1970) Age at first birth and breast cancer risk. Bull World Health Organ 43(2):209–221PubMedPubMedCentral

22.

Brinton LA, Hoover R, Fraumeni JF Jr (1983) Reproductive factors in the aetiology of breast cancer. Br J Cancer 47(6):757–762PubMedPubMedCentralCrossRef

23.

The World Bank. http://data.worldbank.org/indicator/SP.DYN.TFRT.IN. Accessed 28 Oct 2015

24.

Forouzanfar MH, Foreman KJ, Delossantos AM et al (2011) Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 378(9801):1461–1484PubMedCrossRef

25.

Sankaranarayanan R, Ferlay J (2006) Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol 20(2):207–225PubMedCrossRef

26.

OECD Health at a glance (2013) http://www.oecd.org/els/health-systems/Health-at-a-Glance-2013.pdf. Accessed 28 Oct 2015

27.

Harlap S, Davies AM, Deutsch L et al (2007) The Jerusalem Perinatal Study Cohort, 1964–2005: methods and a review of the main results. Paediatr Perinat Epidemiol 21(3):256–273PubMedPubMedCentralCrossRef

28.

Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB (eds) (2000) Cancer incidence in five continents. IARC Press (IARC scientific publications no. 155), Lyon

29.

Fishler Y, Chetrit A (1997) First nationwide Cancer Registry data quality control survey in Israel: Israel Center for Disease Control, cancer program area. J Regist Manage 24(2):50–54

30.

International classification of diseases for oncology, 3rd Edition (ICD-O-3), WHO (2000) http://www.who.int/classifications/icd/adaptations/oncology/en. Accessed 28 Oct 2015

31.

Lane-Claypon JE (1926) A further report on cancer of the breast with special references to its associated antecedent conditions. Reports on public health and medical subjects No. 32. Ministry of health London: Published by his majesty’s stationary office

32.

Hinkula M, Pukkala E, Kyyronen P, Kauppila A (2001) Grand multiparity and the risk of breast cancer: population-based study in Finland. Cancer Causes Control 12(6):491–500PubMedCrossRef

33.

Russo IH, Russo J (2011) Pregnancy-induced changes in breast cancer risk. J Mammary Gland Biol Neoplasia 16(3):221–233PubMedCrossRef

34.

Britt K, Ashworth A, Smalley M (2007) Pregnancy and the risk of breast cancer. Endocr Relat Cancer 14(4):907–933PubMedCrossRef

35.

Collaborative Group on Hormonal Factors in Breast Cancer (2002) Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 360(9328):187–195CrossRef

36.

Hinkula M, Pukkala E, Kyyronen P, Kauppila A (2002) Grand multiparity and incidence of endometrial cancer: a population-based study in Finland. Int J Cancer 98(6):912–915PubMedCrossRef

37.

Hinkula M, Pukkala E, Kyyronen P, Kauppila A (2006) Incidence of ovarian cancer of grand multiparous women—a population-based study in Finland. Gynecol Oncol 103(1):207–211PubMedCrossRef

38.

Hinkula M, Pukkala E, Kyyronen P et al (2004) A population-based study on the risk of cervical cancer and cervical intraepithelial neoplasia among grand multiparous women in Finland. Brit J Cancer 90(5):1025–1029PubMedPubMedCentralCrossRef

39.

Dossus L, Allen N, Kaaks R et al (2010) Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 127(2):442–451PubMed

40.

Haidopoulos D, Simou M, Akrivos N, Rodolakis A, Vlachos G, Fotiou S et al (2010) Risk factors in women 40 years of age and younger with endometrial carcinoma. Acta Obstet Gynecol Scand 89(10):1326–1330PubMedCrossRef

41.

Salvesen HB, Akslen LA, Albreksten G, Iversen OE (1998) Poorer survival of nulliparous women with endometrial carcinoma. Cancer 82(7):1328–1333PubMedCrossRef

42.

Albreksten G, Heuch I, Wik E, Salvesen HB (2009) Parity and time interval since childbirth influence survival in endometrial cancer patients. Int J Gynecol Cancer 19(4):665–669CrossRef

43.

Albreksten G, Heuch I, Wik E, Salvesen HB (2009) Prognostic impact of parity in 493 uterine sarcoma patients. Int J Gynecol Cancer 19(6):1062–1067CrossRef

44.

Hachisuga T, Fukuda K, Hirakawa T, Kawarabayashi T (2001) The effect of nulliparity on survival in endometrial cancer at different ages. Gynecol Oncol 82(1):122–126PubMedCrossRef

45.

Marth C, Windbichler G, Petru E et al (1997) Parity as an independent prognostic factor in malignant mixed mesodermal tumors of the endometrium. Gynecol Oncol 64(1):121–125PubMedCrossRef

46.

Barnett GC, Shah M, Redman K, Easton DF, Ponder BAJ, Pharoah PDP (2008) Risk factors for the incidence of breast cancer: do they affect survival from the disease? J Clin Oncol 26(20):3310–3316PubMedCrossRef

47.

Butt S, Borgquist S, Garne JP et al (2009) Parity in relation to survival following breast cancer. Eur J Surg Oncol 35(7):702–708PubMedCrossRef

48.

Warren Andersen S, Newcomb PA, Hampton JM, Titus-Ernstoff L, Egan KM, Trentham-Dietz A (2011) Reproductive factors and histologic subtype in relation to mortality after a breast cancer diagnosis. Breast Cancer Res Treat 130(3):975–980PubMedCrossRef

49.

Kadi M, Wark PA, Gunter MJ, Riboli E (2012) Parity and mortality from causes other than breast cancer in breast cancer patients. Breast Cancer Res Treat 131(3):1077–1081PubMedCrossRef

50.

Trivers KF, Gammon MD, Abrahamson PE et al (2007) Association between reproductive factors and breast cancer survival in younger women. Breast Cancer Res Treat 103(1):93–102PubMedCrossRef

51.

Kotsopoulos J, Chen WY, Gates MA, Tworoger SS, Hankinson SE, Rosner BA (2010) Risk factors for ductal and lobular breast cancer: results from the nurses’ health study. Breast Cancer Res 12(6):R106PubMedPubMedCentralCrossRef

52.

Albreksten G, Heuch I, Thoresen S (2010) Histological type and grade of breast cancer tumors by parity, age at birth, and time since birth: a register-based study in Norway. BMC Cancer 10:226CrossRef

53.

Palmer JR, Boggs DA, Wise LA, Ambrosone CB, Adams-Campbell LL, Rosenberg L (2011) Parity and lactation in relation to estrogen receptor negative breast cancer in African American women. Cancer Epidemiol Biomarkers Prev 20(9):1883–1891PubMedPubMedCentralCrossRef

54.

Yang XR, Chang-Claude J, Goode EL et al (2011) Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst 103(3):250–263PubMedPubMedCentralCrossRef

55.

Lara-Medina F, Perez-Sanchez V, Saavedra-Perez D et al (2011) Triple-negative breast cancer in Hispanic patients. Cancer 117(16):3658–3669PubMedCrossRef

56.

Phipps AI, Chlebowski RT, Prentice R et al (2011) Reproductive history and oral contraceptive use in relation of triple-negative breast cancer. J Natl Cancer Inst 103(6):470–477PubMedPubMedCentralCrossRef

57.

Curigliano G, Godlhirsch A (2011) The triple-negative subtype: new ideas for the poorest prognosis breast cancer. J Natl Cancer Inst Monogr 43:108–110CrossRef

58.

Metzger-Filho O, Sun Z, Viale G et al (2013) Patterns of recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX. J Clin Oncol 31(25):3083–3090PubMedPubMedCentralCrossRef

59.

Alsaker MDK, Opdahl S, Romundstad PR, Vatten LJ (2013) Association of time since last birth, age at first birth and parity with breast cancer survival among parous women: a register-based study from Norway. Int J Cancer 132(1):174–181PubMedCrossRef

60.

Zhao W, Grubbs CJ, Myers RK, Nilsen-Hamilton M (2010) Parity is associated with an expanded macrophage population in the mammary gland. Int J Oncol 37(5):1195–1202PubMed

61.

Asztalos S, Gann PH, Hayes MK et al (2010) Gene expression patterns in the human breast after pregnancy. Cancer Prev Res 3(3):301–311CrossRef

62.

Ever-Hadani P, Seidman DS, Manor O, Harlap S (1994) Breast feeding in Israel: maternal factors associated with choice and duration. J Epidemiol Community Health 48(3):281–285PubMedPubMedCentralCrossRef

63.

Birenbaum-Carmeli D (2008) Your faith or mine: a pregnancy spacing intervention in an ultra-orthodox Jewish community in Israel. Reprod Health Matters 16(32):185–191PubMedCrossRef

64.

Baron-Epel D (2010) Attitudes and beliefs associated with mammography in a multiethnic population in Israel. Health Educ Behav 37(7):227–242PubMedCrossRef

65.

Struewing JP, Hartge P, Wacholder S et al (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336(20):1401–1408PubMedCrossRef

66.

Oddoux C, Struewing JP, Clayton CM et al (1996) The carrier frequency of the BRCA2 6174 delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 14(2):188–190PubMedCrossRef

67.

Roa BB, Boyd AA, Volcik K, Richards CS (1996) Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14(2):185–187PubMedCrossRef

68.

Brinton LA, Sakoda LC, Sherman ME et al (2005) Relationship of benign gynecologic diseases to subsequent risk of ovarian and uterine tumors. Cancer Epidemiol Biomarkers Prev 14(12):2929–2935PubMedCrossRef

Titel: Grand multiparity and reproductive cancer in the Jerusalem Perinatal Study Cohort
verfasst von: Ora Paltiel
Salman M. Tajuddin
Yelena Polanker
Shoshanah Yazdgerdi
Orly Manor
Yechiel Friedlander
Susan Harlap
Ronit Calderon-Margalit
Publikationsdatum: 01.02.2016
Verlag: Springer International Publishing
Erschienen in: Cancer Causes & Control / Ausgabe 2/2016
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-015-0701-6

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Grand multiparity and reproductive cancer in the Jerusalem Perinatal Study Cohort